drugset / Trial / NCT02505334
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.
Timeline
- Start
- 2015-07-21
- Primary completion
- 2017-05-02
- Completion
- 2017-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 0.9 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |